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1. Introduction
Diabetic foot disease is an important problem confronting the diabetologist, 
internists, and surgeons as it reduces patient’s quality of life and affects social par-
ticipation. It is including several chronic complications as infection, foot ulceration 
and even tissue destruction of the foot. These complications are considered as a sig-
nificant cause of morbidity and mortality among diabetic patients. Consequently, 
chronic complications or diabetic foot disease are a growing concern worldwide and 
represent a major global medical, social, and economic problem.
Diabetic Foot Ulcer (DFU) is one of the most distressing complications and it is 
defined as the commonest major end-point of diabetic foot disease.
The main etiological factors for DFU are peripheral nerves damage and peripheral 
vascular disease. Series of mechanisms are documented such as decreased peripheral 
blood flow and decreased local angiogenesis.
Furthermore, biomechanical abnormalities and increased susceptibility for 
infection are associated factors exposing to DFU [1, 2].
2. Etiopathogenesis
The etipathogenesis of diabetic foot disease is multifactorial with major factors. 
Neuropathy, microvascular disease and infection are mainly included. These factors 
are leading to foot tissue necrosis and ulcer occurrence [2, 3]. 
2.1 Neuropathy in diabetic foot
About 50% of patients with diabetes mellitus develop symptomatic peripheral 
neuropathy within 25 years of disease onset. Distal polyneuropathy is commonly 
encountered. Whereas combined neuropathies with motor and autonomic fibers 
involvement can occur. Age, disease duration and poor glyceamic control quality 
over several years are strong predictors, leading to diabetic neuropathy [4].
Hyperglycemia, dyslipidemia, insulin resistance and oxidative stress can con-
tribute to diabetic neuropathy [5].
According to Rochester Study [6], the severity of the neuropathy is related to the 
duration of hyperglycemia exposure. Other factors are studied in current researchs 
focusing on oxidative stress, advanced glycation-end products, protein kinase C 
and the polyol pathway [7].
The Eye and Foot in Diabetes
2
2.2 Vasculopathy
Peripheral vascular disease is among the main etiological factors in foot ulcer-
ation. Chronic hyperglycemia causes peripheral arteries damage, smooth cell 
abnormalities and endothelial cell dysfunction.
Endothelial dysfunction, owing to changes in the proliferation of endothelial 
cells, thickening of the basement membrane, leads essentially to microvascular 
disease which is responsible for ischemia. Hyperglycemia is also associated with an 
increase in thromboxane A2 leading to plasma hypercoagulability [8].
2.3 Immunopathy
The immune system is compromised with hyperglycemia and research indi-
cates the impairment of the immune system with serum glucose levels exceeding 
to 150 ml/dl. Thus, high blood glucose levels lead to inappropriate inflammatory 
response and disruption of cellular immunity (inhibition of fibroblast prolifera-
tion and impairment of the basal layer of keratinocytes, reducing epidermal cell 
migration) [8].
Consequently, diabetic patients are more exosed to the foot infection which is a 
limb-threatening and debilitating condition mainly seen in incontrolled diabetes. 
The soft tissue infection adversely affects diabetic control. This repetitive cycle 
leads to uncontrolled hyperglycemia, further affecting the immune response to 
infection [9]. The bone can be involved in case of infection resistance responsible 
for soft tissue infection dissemination making osteitis.
Bad glycemia control associated with an open wound creates a catabolic state 
and a metabolic dysfunction affecting the synthesis of proteins, collagen and fibro-
blasts. Furthermore, systemic deficiencies are propagated leading to  nutritional 
compromise in diabetes [10].
3. Classification
Many classifications of the diabetic foot are reported. The most commonly used 
is Wagner’s classification, consisting of six simplistic wound grades used to assess 
ulcer depth (grades 0–5) [11]. This classification is limited as it is not able to recog-
nize ischaemia and infection as independent risk factors in all classification grades 
[12]. A more recently proposed and popularized DFU classification is the University 
of Texas Wound Classification [13].
4. Clinical presentation
Clinical foot examination at each follow-up is important to detect the disease 
early such as ulceration or gangrene. The clinical examination includes inspection 
of the skin integrity, foot deformities such as, Charcot’s foot, hallux valgus, claw 
toe, hollow foot, skew or flat foot. The muscular condition and the bone structure 
should be evaluated as well [4].
Hyperkeratosis with dry and fissured skin are features of polyneuropathy. Lower 
extremity vascular insufficiency is made by one or more signs of claudication, night 
or rest pain, atrophic integument, absent peripheral pulses and loss of limb hair [8].
About 50% of patients with DFU present clinical signs of infection which is 
clinically featured by the presence of purulent secretions or at least two of the 
inflammatory classic signs (painful swelling, edema, hyperemia). The lack of the 
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sensitivity in patients with impaired immune response due to neuropathy can 
make these signs masked [8].
5. Investigations
Guideline development group selected recommendations from the National 
Institute of Clinical Excellence. In their most recent publishment, the annual 
assessment of the diabetic foot requires recommendations aiming essentially to 
assess both of peripheral neuropathy and peripheral vascular status.
Peripheral vascular disease is diagnosed by angiography which studies the 
peripheral arterial tree. Non-invasive vascular screening is currently more used in 
the diabetic foot to detect early the peripheral ischemia [14].
These investigations consist of Doppler ultrasound (for estimation of ankle 
brachial ratio), photo-plethysmography, transcutaneous oximetry, laser Doppler 
flowmetry and television microscopy [2].
Most guidelines recommend the use of Neurological foot testing with 10 g 
monofilament in order to assess diabetic neuropathy. An inability to sense a 10 g 
pressure is the current consensus definition of loss of protective sensation [15].
6. Management
The management of the diabetic foot complications is multidisciplinary and 
requires the collaboration of a specialist team comprising a dialectologist, surgeons, 
podiatrist, microbiologist, tissue viability nurse with a thorough understanding of 
foot function.
The aim is to decrease the risk of the disease progression leading to feet defor-
mities, ulcers and foot amputation. The prognosis is mainly highlighted by factors 
such as glycaemic and blood pressure control, diabetic nephropathy and diabetic 
retinopathy [16].
6.1 Conservative therapeutic modalities
6.1.1 Glycemic control
It is demonstrating that a good controlled glycaemia delays the onset and slows 
the progression of diabetic neuropathy, retinopathy and nephropathy in patients 
with insulin-dependent diabetes mellitus [17, 18].
Callaghan et al. [12] showed the decrease in the risk of developing clinical 
neuropathy with better glycaemic control, in diabetes requiring insulinotherapy.
6.1.2 Pharmacological therapy
The medication adherence to oral diabetic drugs is improved by the patient 
education. The pain resulting from the distal neuropathy requires the use of pain 
killers. The National Institute of Clinical Excellence recommends use of first-line 
agent duloxetine and pregabalin for pain control [19].
Various risk factors for atherosclerosis mainly smoking, should be completely 
stopped in diabetic patients in order to decrease the risk of distal vascular disease. 
Adding to that the use of statins and antiplatelet medications reduce the limb 
ischemia risk and the vascularisation, when it is improved, it is in turn associated 
with a reduced amputation rate.
The Eye and Foot in Diabetes
4
A targeted antibiotherapy based on the wound culture results is needed in DFU 
with superadded infection. The duration of treatment depends on the underlying 
infection severity [20].
6.1.3 Debridement
A 10-year review on standardized wound care protocol and integrated multi-
disciplinary team showed a reduction in amputation rate in diabetic foot patients as 
they had not delayed debridement [21].
Disease activity is measured by the degree of swelling, erythema and especially 
skin temperature. Superficial ulcer requires the removal of necrotic and hyperkera-
totic tissue as it promotes better the wound healing. Whereas, Deep wounds with 
bone and soft tissue involvement need more aggressive debridement with some 
involving surgery [20].
6.1.4 Foot pressure relief
The most important therapeutic principle is typically based on a quick and 
consistent pressure relief to promote wound healing as the weight bearing force 
is removed from the site of ulcer. The force redistribution is ensured by means of 
temporary immobilization, wearing of a protective cast or orthosis [22].
6.1.5 Wound dressings
A variety of dressing modalities are available with the advancement in the 
promotion of wound healing.
Dressing materials can be of various categories including natural, modified and 
synthetic polymers, as well as their mixtures or combinations, processed in the 
Figure 1. 
Wet gangrene of the toe with osteitis. Complete healing under antibiotic treatment and MMP’s inhibitor 
(pharysor).
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form of films, foams, hydrogels and hydrocolloids. Furthermore, wound dressings 
can be used as medicated systems, through the delivery of healing enhancers and 
therapeutic substances (growth factors, peptides, drugs, stem cells and/or other 
bioactive substances) [2].
Randomized controlled trials [23], showed that Silver-impregnated dressings 
have not been shown to be more efficient in treating DFU.
Furthermore, “Moist dressings” are suggested to be more efficient than “dry 
dressings.” [24].
According to our experience in the “Olivier Private Clinic”, Sousse, Tunisia.
We noted the efficiency of Matrix Metalloproteinases (MMPs) inhibitors of 
natural or synthetic origin in the healing process of chronic diabetic wounds. We 
use mainly moist dressings with Pharysor*, a MMPs inhibitor of natural origin, 
in diabetes with superficial and even with deep chronic ulcers. This agent has been 
found to be beneficial in improving wound healing rates (Figures 1–4).
Adding to that, our standard non-surgical management for DFU requires nega-
tive pressure wound therapy, close glycemic control and nutritional support with 
enriched oral nutritional supplement. A targeted antibiotherapy is further delivered 
in infected ulcers.
Figure 2. 
Wet gangrene of the second toe with osteo-arthritis. Complete healing under antibiotic treatment and MMP’s 
inhibitor (pharysor).
Figure 3. 
Wet gangrene of the forefoot complete healing under antibiotic treatment and MMP’s inhibitor (pharysor).
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6.2 Surgical management of DFU
Surgeons interfere in the second line and surgical approach becomes necessary 
when conservative and medical alternatives are not sufficient. All reconstructive 
surgery techniques, in particular local flaps and skin grafts, can be used depending 
on the location and size of the substance loss.
Furthermore, possibilities of revascularization of the lower limbs are needed to 
improve the chances of skin healing in case of limb ischemia.
The therapeutic decision of partial leg amputation is not systematic and should 
be taken as a last therapeutic option. Amputation is typically recommended for 
deep and chronic non healing ulcers with necrotic tissues.
7. Prevention
Preventive strategies are important to decrease the risk of repeated ulcers and 
amputation. Measures are mainly based on patient education and foot assessements 
for peripheral vascular disease and neuropathy. Furthermore, foot pressure relief 
with individualized orthopedic shoe provision and insole treatment is necessary 
in order to adapt the pressure distribution to each foot. Consequently, lesions and 
chronic foot ulcers may be better prevented.
8. Conclusion
Diabetic foot is a chronic complication which poses challenges in the early 
diagnosis and management. Paying attention to this complication is necessary 
during the follow-up of diabetes. The treatment is often conservative with a proper 
glycemic control. Management of risk factors including peripheral vascular disease, 
neuropathy and infection is essential to avoid serious complications leading to 
amputation.
Figure 4. 
Gangrene with osteitis of the calcaneus complete healing under antibiotic treatment, excision  and MMP’s 
inhibitor (pharysor).
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